Search Results - "Enting, Deborah"

Refine Results
  1. 1

    Immune Responses in Bladder Cancer-Role of Immune Cell Populations, Prognostic Factors and Therapeutic Implications by Joseph, Magdalene, Enting, Deborah

    Published in Frontiers in oncology (20-11-2019)
    “…Immunosurveillance, which describes the immunologically mediated elimination of transformed cells, has been widely accepted in the context of bladder cancer…”
    Get full text
    Journal Article
  2. 2

    The incidence and prevalence of upper tract urothelial carcinoma: a systematic review by Soualhi, Ahmed, Rammant, Elke, George, Gincy, Russell, Beth, Enting, Deborah, Nair, Rajesh, Van Hemelrijck, Mieke, Bosco, Cecilia

    Published in BMC urology (17-08-2021)
    “…Upper tract urothelial carcinoma (UTUC) is a rare urological cancer that is still an important public health concern in many areas around the world. Although…”
    Get full text
    Journal Article
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7

    Is there a role for physical activity when treating patients with cancer with immune checkpoint inhibitors? Protocol for a scoping review by Chen, Miaoqi, Rai, Ridesh, Fox, Louis, Moss, Charlotte Louise, George, Gincy, Karagiannis, Sophia N, Enting, Deborah, Joseph, Magdalene, Peat, Nicola, Russell, Beth, Van Hemelrijck, Mieke

    Published in BMJ open (08-10-2021)
    “…IntroductionFor patients with cancer, immune checkpoint inhibitors (ICIs) produce superior long-term responses compared with alternative treatments, although…”
    Get full text
    Journal Article
  8. 8

    Cohort profile: King's Health Partners bladder cancer biobank by Kotecha, Pinky, Moss, Charlotte L, Enting, Deborah, Gillett, Cheryl, Joseph, Magdalene, Josephs, Debra, Rudman, Sarah, Hughes, Simon, Cahill, Fidelma, Wylie, Harriet, Haire, Anna, Rosekilly, James, Khan, Muhammad Shamin, Nair, Rajesh, Thurairaja, Ramesh, Malde, Sachin, Van Hemelrijck, Mieke

    Published in BMC cancer (25-09-2020)
    “…Bladder cancer (BC) is the 9th most common cancer worldwide, but little progress has been made in improving patient outcomes over the last 25 years. The King's…”
    Get full text
    Journal Article
  9. 9
  10. 10
  11. 11
  12. 12

    Hypersensitivity reactions to paclitaxel with a modified dexamethasone intravenous premedication regimen by Vanita Noronha, Deborah Enting, Ravi Thippeswamy, Amit Joshi, Vijay Maruti Patil, Kumar Prabhash

    “…Background: The conventional paclitaxel premedication regimen consists of two oral dexamethasone doses of 20 mg each taken 12 h and 6 h before paclitaxel…”
    Get full text
    Journal Article
  13. 13
  14. 14
  15. 15

    Abstract PO-095: The PROState AI Cancer–Decision Support (PROSAIC-DS) pilot study: Clinical decision support technology and its role in prostate cancer MDT meetings by Santis, Vishal, Enting, Deborah, Patkar, Vivek, Chalkidou, Anastasia, Fox, John, Ruta, Danny, Makanjuola, Jonathan K.

    Published in Clinical cancer research (01-03-2021)
    “…Abstract Background Multidisciplinary teams (MDT/tumour boards) were first introduced in the 1990s and have experienced little change to their methodology…”
    Get full text
    Journal Article
  16. 16
  17. 17

    Systemic anticancer therapy for urothelial carcinoma: UK oncologists’ perspective by Jones, Robert J., Crabb, Simon J., Linch, Mark, Birtle, Alison J., McGrane, John, Enting, Deborah, Stevenson, Robert, Liu, Kin, Kularatne, Bihani, Hussain, Syed A.

    Published in British journal of cancer (06-04-2024)
    “…Urothelial carcinoma (UC) is a common cancer associated with a poor prognosis in patients with advanced disease. Platinum-based chemotherapy has remained the…”
    Get full text
    Journal Article
  18. 18
  19. 19
  20. 20